Abstract
To evaluate cost-effectiveness of pembrolizumab plus chemotherapies for first-line treatment of locally advanced unresectable or metastatic triple negative breast cancer (mTNBC), from the French healthcare system perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
